Multiple growth pathways lead to enhanced proliferation in malignant cells. However, how the core machinery of DNA replication is regulated by growth signaling remains largely unclear. The sliding clamp proliferating cell nuclear antigen (PCNA) is an indispensable component of the DNA machinery responsible for replicating the genome and maintaining genomic integrity. We previously reported that epidermal growth factor receptor (EGFR) triggered tyrosine 211 (Y211) phosphorylation of PCNA, which in turn stabilized PCNA on chromatin to promote cell proliferation. Here we show that the phosphorylation can also be catalyzed by the non-receptor tyrosine kinase c-Abl. We further demonstrate that, in the absence of EGFR, signaling to PCNA can be attained through the activation of the Ron receptor tyrosine kinase and the downstream non-receptor tyrosine kinase c-Abl. We show that Ron and c-Abl form a complex, and that activation of Ron by its ligand, hepatocyte growth factor-like protein (HGFL), stimulates c-Abl kinase activity, which in turn directly phosphorylates PCNA at Y211 and leads to an increased level of chromatin-associated PCNA. Correspondingly, HGFL-induced Ron activation resulted in Y211 phosphorylation of PCNA while silencing of c-Abl blocked this effect. We show that c-Abl and Y211 phosphorylation of PCNA is an important axis downstream of Ron, which is required for cell proliferation. Treatment with a specific peptide that inhibits Y211 phosphorylation of PCNA or with the c-Abl pharmacological inhibitor imatinib suppressed HGFL-induced cell proliferation. Our findings identify the pathway of Ron-c-Abl-PCNA as a mechanism of oncogene-induced cell proliferation, with potentially important implications for development of combination therapy of breast cancer.
INTRODUCTION
Proliferating cell nuclear antigen (PCNA) is an indispensable protein for cell proliferation. PCNA functions as a sliding clamp encircling the DNA double helix. [1] [2] [3] [4] [5] [6] [7] [8] [9] Three molecules of PCNA form a homotrimeric ring on chromatin and act as the molecular platform to recruit other proteins involved in DNA synthesis, cell-cycle control, and DNA damage response and repair. 1, 6, [9] [10] [11] Although it is generally agreed that these tasks of PCNA are coordinated by many different binding partners and post-translational modifications of the sliding clamp, the molecular mechanisms coordinating PCNA functions remain largely unaddressed. We previously reported that PCNA is phosphorylated at the tyrosine residue 211 (Y211), which resulted in stabilization of PCNA on chromatin in breast cancer cells overexpressing epidermal growth factor receptor (EGFR). 12 Inhibition of EGFR by its kinase inhibitor blocked Y211 phosphorylation and resulted in degradation of PCNA on chromatin. It remained to be determined whether Y211 phosphorylation takes place in EGFRnegative cells and, if so, through what signaling mechanisms.
To address this issue, we screened a microarray containing functional protein domains with a fluorescence-labeled Y211 sequence peptide probe, and identified that the phospho-Y211 motif is specifically associated with the Src homolog 2 domain derived from c-Abl. 13 The c-Abl proto-oncogene is a ubiquitous non-receptor tyrosine kinase that shuttles between the cytoplasm and the nucleus. 14 It functions in multiple cellular activities, including normal development, 15 gene expression, 16, 17 cell morphology and migration, 18, 19 response to DNA damage stress, 13, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] survival [37] [38] [39] and proliferation. 39 In breast cancer, activated c-Abl kinase promotes cell survival and invasion 13, [40] [41] [42] and resistance to anti-estrogen treatment. 43, 44 Our recent studies have also shown that c-Abl overexpression is a frequent event in breast cancer (B40%) and has a role in advanced breast cancer. 44 c-Abl may function as a signaling switchboard in cancer cells and may be an important target for cancer therapy. 41, 45 c-Abl is subject to a tight regulation in normal cells. However, in cancer cells, this regulation is abolished and the deregulated c-Abl contributes to tumor development. 40, 41, 45, 46 EGFR is known to interact with c-Abl and the crosstalk between these two kinases results in c-Abl activation. 47, 48 However, how c-Abl is activated in the absence of EGFR is not known.
The receptor tyrosine kinase Ron, also known as macrophagestimulating protein 1 receptor, is a cell surface receptor tyrosine kinase of the c-Met family and has been identified as a major player in the development of multiple types of epithelial cancers. 49 The Ron receptor contains an extracellular ligandbinding domain, a transmembrane domain and an intracellular domain harboring tyrosine kinase activity. Activation of the Ron receptor by its only known ligand, hepatocyte growth factor-like protein (HGFL, also known as macrophage-stimulating protein (MSP)), leads to activation of multiple downstream signaling pathways including PI-3K, mitogen-activated protein kinase and Src. 50, 51 Forced overexpression of the Ron kinase transformed normal cells and led to increased cell proliferation. 52 Overexpression of Ron selectively in mouse mammary epithelium caused breast tumor formation with an associated proliferative phenotype while loss of Ron lead to decreased breast tumor cell growth. 53, 54 Although expressed at low level in most normal tissues, upregulation of Ron expression is a frequent pathological event in breast cancer and has been associated with disease progression and poor outcome. [55] [56] [57] [58] [59] It remains to be determined how Ron promotes cell proliferation and what signaling pathways downstream from the Ron receptor are important in this process.
In this study, we identify the novel pathway of Ron-Abl-PCNA as a mechanism of oncogene-induced cell proliferation. We demonstrate that PCNA is a new substrate of c-Abl and that Ron stimulates Y211 phosphorylation of PCNA through c-Abl in an EGFR-independent manner. Phosphorylation of PCNA at Y211 is a key event downstream of Ron signaling for cell proliferation in vitro and in tumor tissues.
RESULTS
We previously identified that c-Abl interacts with PCNA and enhances cell proliferation in breast cancer cells. 13 To determine whether c-Abl can directly phosphorylate PCNA at Y211, a glutathione S-transferase (GST) fusion protein of wild-type PCNA and a mutant PCNA in which the Y211 residue was replaced with phenylalanine (Y211F) were incubated with recombinant c-Abl kinase in the presence of [g-32 P]ATP. A mutant GST fusion protein with all seven tyrosine residues of PCNA substituted with phenylalanine (7F) was used as a negative control (Figure 1a) . Wild-type GST-PCNA was significantly phosphorylated by c-Abl. The phosphorylation was abolished in Y211F PCNA to a level as low as that of the 7F mutant, suggesting that Y211 is the sole phosphorylation site in PCNA catalyzed by c-Abl. Consistent with the in vitro kinase assay, the levels of Y211 phosphorylation is lower in MCF-7 cells, which have low level of c-Abl kinase activity, compared with BT474 and T47D, which have relatively higher c-Abl kinase activity (Figure 1b) .
Our previous report showed that EGFR phosphorylates PCNA Y211 in MDA-MB-468 cells, which express high levels of EGFR. 12 Certain other breast cancer cell lines, such as T47D and BT474, express very low levels of EGFR, but they express similar levels of Y211-phosphorylated PCNA as MDA-MB-468 cells (Figure 2) . However, unlike MDA-MB-468 cells, treatment with lapatinib, a potent inhibitor of EGFR family members EGFR and ERBB2/HER2, did not result in downregulation of phospho-Y211 PCNA in T47D and BT474 cells (Figure 2a) . The treatment effectively inhibited EGFR and ERBB2 activity as demonstrated by the overall and receptor-specific tyrosine phosphorylation (Figure 2b ). These results indicate that Y211 phosphorylation of PCNA can be induced via an EGFR-and ERBB2-independent mechanism in T47D and BT474 cells. We noticed that c-Abl is expressed at higher levels in the T47D and BT474 cell lines than in MDA-MB-468 cells (Figure 2c) . Phosphorylation of the endogenous adaptor protein CrkL at tyrosine 207, a well-known signaling event directly catalyzed by c-Abl, 60 was also increased in these two cell lines in comparison with MDA-MB-468 (Figure 2c ). These results suggested that Y211 phosphorylation of PCNA in BT474 and T47D cells with low EGFR expression is mediated by a pathway in which the c-Abl kinase is activated. To further establish the causal relationship between c-Abl and the signaling event, mouse embryonic fibroblasts with the endogenous c-Abl gene deleted (Abl À / À ) and the corresponding mouse embryonic fibroblasts with a reconstituted c-Abl gene at a physiological level (Abl þ ) 61, 62 were compared for the level of phospho-Y211 PCNA (Figure 2d Figure 1) . These results together show that c-Abl is an important kinase for Y211 phosphorylation.
Along with others, we have shown that the Ron receptor tyrosine kinase regulates cell growth in breast cancer cells, including T47D. 58, 63 To test the role of Ron signaling and c-Abl in phosphorylation of PCNA at Y211, T47D cells were infected with a lentiviral vector expressing a specific shRNA against c-Abl (shAbl) in the presence and absence of the Ron ligand HGFL. The results show that depleting c-Abl abrogated Y211 phosphorylation, whereas treatment with HGFL significantly stimulated Y211 phosphorylation ( Figure 3) . Importantly, HGFL failed to induce Y211 phosphorylation when c-Abl is depleted, indicating that c-Abl is required for HGFL-induced PCNA phosphorylation. This requirement of c-Abl for induction is specific to PCNA, since , and T47D were examined for the levels of Y211 phosphorylation of PCNA in the presence or absence of the EGFR inhibitor lapatinib (5 mM) for 40 h. Cells were then lysed and phospho-Y211 PCNA was measured by immunoprecipitation with the anti-phospho-Y211 antibody, followed by western analysis using a total PCNA antibody. Lower panels, the relative intensities of phospho-Y211 PCNA were quantitated using NIH ImageJ software (NIH, Bethesda, MA, USA) and normalized to the levels of total PCNA. (b) Lapatinib effectively repressed activity of EGFR and ERBB2. Cells were treated with lapatinib 10 uM for 48 h. Specific antibodies against total tyrosine phosphorylation migrated at B180 kDa (Cell Signaling), phospho-EGFR at Y1068 (p-EGFR), and phospho-ErbB2/HER2 at Y1221/1222 (p-HER2) were used to determine the phosphorylation levels by western analysis of whole-cell lysates. (c) Low EGFR expression and high Ron expression in T47D and BT474 cells. The protein levels of EGFR, Ron, c-Abl, CrkL, phospho-CrkL (p-CrkL) and PCNA were measured by western analysis. (d) Total cell lysates were isolated from mouse embryonic fibroblast (MEF) cells in which the endogenous c-Abl is deleted and stably reintroduced with a retroviral vector-expressing c-Abl (Abl þ ) or the control vector (Abl À / À ), and the level of Y211 phosphorylation was determined by immunoprecipitation and western analysis as described in (a). Figure 3 . HGFL stimulates Y211 phosphorylation through c-Abl. T47D cells were starved for 24 h, followed by stimulation with 80 ng/ml of HGFL for 30 min. Cells were then lysed and the levels of phospho-Y211 PCNA and the indicated proteins were analyzed by western analysis using the corresponding specific antibodies. T47D/shRon but not T47D/shCtrl cells (Figure 4d ). These results suggest that c-Abl is phosphorylated in association with Ron. This possibility was tested using an immunocomplex kinase assay in which the endogenous Ron protein was immunoprecipitated from T47D cells. The isolated Ron was incubated with c-Abl, which was ectopically expressed in and immunoprecipitated from HEK293T cells in a kinase reaction containing [g-32 P]ATP (Figure 4e ). The isolated Ron, but not the control immunoprecipitate by immunoglobulin G, was able to mediate c-Abl phosphorylation. These results together show a potential signaling pathway of HGFL-Ron-Abl-PCNA during cancer cell proliferation.
Corroborating these observations, stimulation with HGFLinduced Y211 phosphorylation of PCNA in serum-starved cells in a time-dependent manner, accompanied by increased levels of phospho-Y207 CrkL and mitogen-activated protein kinase phosphorylation (Figure 5a ). Conversely, Ron depletion in cells cultured in serum-supplemented normal medium caused decreased Y211 phosphorylation of PCNA (Figure 5b ). These results indicated that Y211 phosphorylation of PCNA is a downstream signaling event triggered by the activated Ron pathway. We have reported the use of a peptide-based strategy to target phospho-Y211 PCNA in which the synthetic peptide spanning the Y211 phosphorylation motif but with the site changed to phenylalanine (termed Y211F peptide) specifically inhibited endogenous Y211 phosphorylation and inhibited cell proliferation. 12, 13, 64 Furthermore, we have previously demonstrated that Y211F peptide treatment conferred a more significant growth inhibition effect in cells expressing c-Abl than in the cells in which c-Abl was depleted. 13 This suggested that Y211 phosphorylation is an important component for cell proliferation in c-Abl-expressing cells. Following this line, we reasoned that if phospho-Y211 PCNA has an important contribution to the cell proliferation-promoting function of Ron, downregulation of Y211 phosphorylation should have a more significant impact on proliferation in cells expressing Ron than cells lacking Ron. As anticipated, treatment with the Y211F peptide, but not the control scrambled peptide, inhibited cell growth (Figure 5c ; comparing control and Y211F peptides). Importantly, knockdown of Ron reduced sensitivity to the peptide in comparison with control cells (Figure 5c ), indicating that Y211 phosphorylation of PCNA induced by Ron has an essential role in promoting cell proliferation.
We previously showed that Y211 phosphorylation stabilized chromatin-bound PCNA, which in turn promoted cell proliferation, 12 and that c-Abl functioned to enhance chromatin association of PCNA in cancer cells. 13 Identification of Y211 phosphorylation of PCNA as a downstream event of the HGFLRon-c-Abl pathway predicts that Ron activation should also enhance chromatin association of PCNA. Indeed, stimulation with HGFL increased chromatin-bound PCNA as shown by the increased level of PCNA resistant to Triton X-100 extraction, whereas there is no difference in the chromatin-unbound pool of PCNA, which is soluble with Triton X-100 extraction (Figure 6a ). The observation that Ron induces c-Abl activation suggests that the Ron-induced chromatin association of PCNA relies on c-Abl. Indeed, the HGFL-induced PCNA chromatin association was abrogated by c-Abl depletion (Figure 6a ), which also suppressed the proliferative effect of HGFL (Figure 6b) . A similar effect was observed with pharmacological inhibition of c-Abl by its kinase inhibitor imatinib (STI571), which abrogated the proliferative effect of HGFL (Figure 6c ). Like imatinib, treatment with the Y211 peptide blocked HGFL-induced cell proliferation (Figure 6c) .
These results predict a correlation between phospho-Y211 PCNA and Ron expression in primary breast cancer tumor tissues.
To test this hypothesis, immunohistochemistry (IHC) analyses were performed using IHC-proven antibodies of Ron, 59 ,65 EGFR, PCNA and phospho-Y211 PCNA 12 in a cohort of breast cancer tumor tissues (see Materials and methods section). As we previously reported, expression levels of EGFR in tumor tissues are strongly correlated with phospho-Y211 PCNA (n ¼ 118; P ¼ 0.0027). Importantly, we found that Ron expression is significantly correlated with Y211 phosphorylation of PCNA in the current cohort of tissues (n ¼ 153; P ¼ 0.048; Table 1 ). No correlation was observed between total PCNA and EGFR (n ¼ 118; P ¼ 0.999) or total PCNA and Ron (n ¼ 162; P ¼ 0.416). These results indicate that both EGFR and Ron are associated with Y211 phosphorylation of PCNA in human breast cancer. EGFR overexpression is a frequent event in this cohort of samples. When examining the samples with low EGFR expression but positive phospho-Y211 PCNA (n ¼ 28), we found that more than half of them (n ¼ 16; 57%) were Ron-positive, indicating that Ron as well as EGFR is associated with Y211 phosphorylation of PCNA in human breast cancer. We then examined the correlation between Ron and phospho-Y211 PCNA with c-Abl. Owing to sample availability, this was examined in another independent cohort of patients (see Materials and methods section). Consistent with the activity of c-Abl in catalyzing Y211 phosphorylation of PCNA, the levels of phospho-Y211 PCNA were significantly correlated with the level of c-Abl (n ¼ 91, P ¼ 0.0008; Table 2 ). However, significant correlation between Ron and c-Abl was not found within this cohort of samples. This suggests that multiple other pathways contribute to the Abl-PCNA cascade. Indeed, among the tissues with relatively low levels of EGFR (H score lower than median) and high levels of phospho-Y211 PCNA (H score higher than medium) and c-Abl (H score higher than median; n ¼ 24), 62.5% of these tissues have high Ron expression (H score above the median). Representative IHC staining of tissues with positive expression of Ron, c-Abl and phospho-Y211 PCNA are shown in Figure 7 .
DISCUSSION
This study identifies c-Abl as a non-receptor tyrosine kinase that is capable of catalyzing Y211 phosphorylation of PCNA in breast cancer cells. We further demonstrate that this pathway is regulated by the receptor tyrosine kinase Ron in EGFR-negative cells. Thus, Y211 phosphorylation of PCNA can be mediated by different kinases in different cell contexts to foster cell proliferation.
We previously showed that the Src homolog 2 domain of c-Abl interacted with the phosphorylated Y211 motif of PCNA and that targeting the phosphorylation resulted in inhibition of breast cancer growth. 13 In this study, we are able to establish a new pathway in which the Ron receptor tyrosine kinase activates c-Abl, which in turn catalyzes Y211 phosphorylation of PCNA. This mechanism may augment the intensity and speed of the signaling mediated by c-Abl. Augmented interaction with the substrate on phosphorylation is a common mechanism adopted by the c-Abl kinase. Examples include c-Jun, 16 RNA polymerase II 66 and p73. 31 For PCNA, this mechanism can provide a unique advantage given its topology as a trimeric ring in which a phosphorylated PCNA unit at Y211 can serve as the docking site of c-Abl that in turn catalyzes phosphorylation on other PCNA units in the same trimer. In addition, binding of c-Abl to the phosphorylated Y211 of PCNA through its Src homolog 2 domain may lend an opportunity for the c-Abl kinase to regulate other proteins associated with the PCNA sliding clamp. In addition, our findings are consistent with the notion that multiple pathways are activated by Ron signaling, such as mitogen-activated protein kinase, which is not dependent on c-Abl, and Y211 phosphorylation of PCNA, which requires c-Abl function. This is the first report, which has shown that c-Abl is regulated by Ron. It is interesting that stimulation with HGFL resulted in decreased levels of the Ron-Abl complex. Although the underlying mechanism remains to be determined, this phenomenon is consistent with an enzyme-substrate relationship between the activated Ron and c-Abl in which the catalyzed substrate is dissociated from the enzyme. It is conceivable that the activated c-Abl undergoes conformation changes, which facilitate its translocation and association with other downstream binding partners. c-Abl has also been shown to regulate receptor tyrosine kinases by phosphorylating the receptors. 47, 48 Thus, the molecular outcome subsequent to the interaction between c-Abl and membrane receptors can be complex. Further molecular characterization of the interaction between Ron and c-Abl in response to HGFL will be necessary to determine the mechanism of crosstalk between these proteins. In addition to molecular evidence derived from breast cancer cell lines, significant correlation between Ron and phospho-Y211 PCNA as well as phospho-Y211 PCNA and c-Abl was also established in archived primary tumor tissues. Although correlation between Ron and T47D cells were starved by maintaining in a medium containing 0.5% of serum for 24 h, then subject to the indicated treatment for 72 h (HGFL, 80 ng/ml, imatinib, 10 mM, peptides, 6 mM). Cell growth was assessed by MTT assay and the data were plotted. ***Po0.001. EGFR has been demonstrated to be able to stimulate c-Abl 40, 67, 68 and EGFR signaling may also lead to Y211 phosphorylation of PCNA through c-Abl, in addition to the direct mechanism in which nucleus-localized EGFR interacts with PCNA and catalyzes the phosphorylation event.
12 PCNA Y211 phosphorylation may be a point of convergence for proliferation signaling governed by EGFR and Ron, as both have significant roles in breast cancer (Figure 8 ). Multiple EGFR-specific small molecules and antibodies have been developed as therapeutic agents in the past decades. However, their impact on breast cancer as single treatments has been disappointing. Thus, development of effective combined therapeutic approaches are desperately needed. 69 Our observation suggests that combined treatment of EGFR and the Ron-Abl axis is a promising strategy to target breast cancer. Combining the EGFR-ERBB2 dual inhibitor lapatinib and the c-Abl inhibitor imatinib resulted in synergistic efficacy in growth inhibition of breast cancer cells. 70 It remains possible that other kinases may also be involved in Y211 phosphorylation of PCNA. Further understanding the signaling mechanisms underlying PCNA phosphorylation can allow this event to be used not only as a prognostic marker for disease development, but also as a therapeutic target of combination treatment in multiple cancer types and to help overcome the frequent challenge of drug resistance in cancer therapy.
MATERIALS AND METHODS
Cell culture and antibodies, and chemicals T47D, BT474 and MDA-MB-468 cell lines were purchased from American Type Culture Collection (Manassas, VA, USA). T47D/shAbl and T47D/shCtrl cells were generated as described previously. 44 The Abl þ and Abl À / À mouse embryonic fibroblasts were derived from double knockout of the mouse Abl and Arg genes, followed by reintroduction of Abl with a retroviral vector (Abl þ ) or a control vector (Abl À / À ) as described previously. 61, 62 All cells were grown in Dulbecco's modified Eagle's medium/F12 (1:1) with 10% fetal bovine serum. The following antibodies were purchased: a-tubulin (from Sigma, St Louis, MO, USA); c-Abl (from EMD/Calbiochem (Billerica, MA, USA) for immunoblot and immunoprecipitation analyses; from Pierce (Rockford, IL, USA) for IHC); EGFR, CrkL, phospho-EGFR (Y1068), phospho-HER2 (Y1221/1222), phospho-Y207-CrkL (from Cell Signaling, Danvers, MA, USA); phospho-PCNA (Bethyl, Montgomery, TX, USA); PCNA, Ron, immunoglobulin G (from Santa Cruz, Santa Cruz, CA, USA), Ron/MSPR (from R&D Systems, Minneapolis, MN, USA). HGFL/MSP was purchased from R&D Systems. Lapatinib and imatinib were purchased from LC Laboratories (Woburn, MA, USA).
Cell growth analysis
Measurement of cell growth was based on the reduction of the tetrazolium salt MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide as described previously. 71 Briefly, 1000 to 3000 cells per well were plated in 96-well plates, in triplicates. The assay was initiated by adding 20 ml of MTT reagent (5 mg/ml in phosphate-buffered saline) to the 100 ml culture and incubated for 4 h. In all, 100 ml of detergent (20% sodium dodecyl sulfate, 50% N,N-dimethylformamide, pH 4.7) was then added to lyse the cells for overnight. Absorbance at 570 nm was recorded. The experiments were repeated at least three times. Figure 7 . Expression of Ron, c-Abl, and phospho-Y211 PCNA in primary breast cancer tissues. Ron, c-Abl and phospho-Y211 PCNA in the tumor tissues were assessed by IHC using specific antibodies as described in the Materials and methods section. Representative staining in two pairs of consecutive tissue sections is shown. The tissues were selected from a tumor microarray purchased from US Biomax (BRC1021). Bar, 100 mm. Figure 8 . Schematic illustration of the Y211 phosphorylation pathways. EGFR has been shown to be able to directly phosphorylate PCNA at Y211. This study demonstrates a new pathway in which stimulation of the Ron receptor induces Y211 phosphorylation through activation of c-Abl, which subsequently catalyzes phosphorylation of PCNA at Y211. Given the fact that Ron, EGFR and c-Abl are important targets in cancer therapy, combined inhibition of phospho-Y211 PCNA may be an efficient approach to enhance sensitivity and help overcome drug resistance.
Kinase assay
To examine PCNA as the substrate of c-Abl, 40 ml of kinase reaction mix contained 50-100 ng of purified c-Abl protein (Upstate, Billerica, MA, USA), and 0.2-0.8 mg of GST-PCNA fusion protein in reaction buffer (10 mM TrisHCl, pH 7.5; 10 mM MgCl2; 1 mM DTT; 10 mM cold ATP) was set up. Kinase reactions were initiated by adding 25-50 mCi of [g-32 P]ATP. After incubating 30 min at room temperature, reactions were stopped by adding 10 ml of 5X loading buffer. 32 P incorporation into GST-PCNA was quantitated using a PhosphorImager (Molecular Dynamics, Champaign, IL, USA). Endogenous c-Abl kinase activities were determined by immunocomplex kinase assay in which the endogenous c-Abl was immunoprecipitated from serum-starved cells and then mixed with recombinant GST-Crk substrate in the presence of [g-32P]ATP as reported previously. 68, 72 For kinase activity of Ron, endogenous Ron was immunoprecipitated from 100 mg of T47D total lysate by a Ron/MSPR-specific antibody (R&D Systems) or a control immunoglobulin G control. The immunoprecipitate was incubated with immunoprecipitate of c-Abl from 100 mg of the lysate of HEK-293T cells, which had been transiently transfected with 10 mg of c-Abl complementary DNA.
Immunohistochemical staining
Correlation among pY211-PCNA and Ron was conducted using consecutive sections of tissue microarrays were purchased from the Cooperative Breast Cancer Tissue Resource (CBCTR) of the National Cancer Institute (NCI, Coral Gables, FL, USA). To examine the correlation between Ron and pY211-PCNA with c-Abl, tissue microarray purchased from US Biomax (Rockville, MD, USA) (BRC1021) were used. IHC was performed as previously described. 12 In brief, paraffin was removed by heating slides at 60 1 C for 1 h, extracted twice with xylene for 10 min, followed by a series of ethanol solutions. Antigen retrieval was conducted by heating in a microwave (90-100 1C) in citrate buffer (10 mM, pH 6.0) for 30 min. Endogenous peroxidase was quenched with 3% H 2 O 2 in methanol. For immunostaining, slides were blocked in 5% goat serum in Tris-buffered saline-tween 20 (TBST; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for 1 h. IHC staining and the scoring of pY211-PCNA and total PCNA, 12 Ron, 59 ,65 c-Abl, 44 and EGFR 12 were conducted following procedures optimized and described previously by our group. IHC staining was scored by the histological scoring method (H score), as defined by the product of the percent positivity and the staining intensity. To test the correlation between different markers, IHC scores were dichotomized as high or low. In the study described in Table 1 , Ron staining dichotomization was based on the medium H score. For other markers, the average H scores are used. In the study described in Table 2 , the medium scores were used for dichotomization for all markers. P-values were determined by Fisher's test. Differences with Pp0.05 were considered statistically significant.
Western analysis
Cell lysates of the treated cells were isolated by incubation with NETN buffer (NaCl-EDTA-Tris-NP40; 150 mM NaCl, 1 mM EDTA pH 8.0, 20 mM Tris pH 8.0, 0.5% NP-40, phosphatase inhibitors consisting of 25 mM NaF and 2 mM Na 3 VO 4 , and the protease inhibitors 20 ml/ml aprotinin and 0.1 M phenylmethylsulfonyl fluoride). Cell lysates were separated on acrylamide gels, transferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA), and probed with the indicated antibodies. Bands were visualized by a chemiluminescence-based detection method (Fisher/Pierce, Rockford, IL, USA) that used a horseradish peroxidase-conjugated secondary antibody.
